| 1.96 0.01 (0.51%) | 07-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.36  |
1-year : | 5.84 |
| Resists | First : | 3.73 |
Second : | 5 |
| Pivot price | 2.77 |
|||
| Supports | First : | 1.7 | Second : | 1.41 |
| MAs | MA(5) : | 1.99 |
MA(20) : | 3.06 |
| MA(100) : | 2.94 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 10 |
D(3) : | 9.7  |
| RSI | RSI(14): 39.3 |
|||
| 52-week | High : | 15.5 | Low : | 1.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RGNT ] has closed above bottom band by 23.3%. Bollinger Bands are 46.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.06 - 2.07 | 2.07 - 2.09 |
| Low: | 1.91 - 1.92 | 1.92 - 1.93 |
| Close: | 1.94 - 1.96 | 1.96 - 1.98 |
Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage. Regentis Biomaterials leverages its proprietary Gelrin platform, which employs biodegradable hydrogel implants, to develop orthopedic therapies that facilitate the regeneration of compromised or diseased tissues. The company was established in 2004 and operates from its headquarters in Herzliya, Israel.
Thu, 23 Jul 2026
Price to book forward of Regentis Biomaterials Ltd. – AMEX:RGNT - TradingView
Mon, 20 Jul 2026
Japanese patent boosts Regentis Biomaterials (NYSE American: RGNT) GelrinC IP - Stock Titan
Thu, 16 Jul 2026
Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process - NewMediaWire
Tue, 14 Jul 2026
REGENTIS BIOMATERIALS LTD. SEC Filing (Jul 14, 2026) - Stock Titan
Thu, 09 Jul 2026
RGNT SEC Filings - Regentis Biomaterials Ltd 10-K, 10-Q, 8-K Forms - Stock Titan
Thu, 09 Jul 2026
Regentis Biomaterials (RGNT) shareholders approve all 14 AGM proposals at adjourned meeting - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|